918501-81-2

Usage

Structure

A piperidine ring with a carboxylic acid group, an ester group, and a 4-[(4-chlorophenyl)methoxymethyl] group attached.

Type of compound

An ester of piperidinecarboxylic acid.

Usage

Frequently used as a building block in organic synthesis and medicinal chemistry.

Potential applications

May have potential applications in the development of pharmaceuticals or other biologically active molecules.

Utility as a prodrug

As an ester, it may have utility as a prodrug, which can be metabolized in the body to release the active form of the compound.

Value in research and development

It is a valuable chemical with diverse potential uses in research and development.

Upstream product

• 74-88-4 methyl iodide 
• 209808-06-0 tert-butyl 4-(4-chlorobenzoyl)piperidine-1-carboxylate 
• 639468-65-8 4-[(4-chlorophenyl)hydroxymethyl]piperidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 918501-82-3 C₁₃H₁₈ClNO 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the specification, for use in therapy.

SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatm

Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists

Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH2)q—, —C(═NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.